Literature DB >> 27238216

Novel biomarker and easy to perform ELISA for monitoring complement inhibition in patients with atypical hemolytic uremic syndrome treated with eculizumab.

Magdalena Riedl1, Johannes Hofer1, Thomas Giner1, Alejandra Rosales1, Karsten Häffner2, Giacomo D Simonetti3, Ulrike Walden4, Tanja Maier5, Dorothea Heininger6, Verena Jeller1, Günter Weiss7, Lambert van den Heuvel8, Lothar B Zimmerhackl1, Reinhard Würzner9, Therese C Jungraithmayr1.   

Abstract

Entities:  

Keywords:  Atypical hemolytic uremic syndrome; Complement activation; Eculizumab; Terminal complement complex; Thrombotic microangiopathies

Mesh：

Substances：

Year:  2016        PMID： 27238216      PMCID： PMC5625999          DOI： 10.1016/j.jim.2016.05.009

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN： 0022-1759            Impact factor:   2.303


× No keyword cloud information.
  42 in total

1.  Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.

Authors:  Lothar Bernd Zimmerhackl; Johannes Hofer; Gérard Cortina; Walter Mark; Reinhard Würzner; Therese C Jungraithmayr; Gus Khursigara; Kay O Kliche; Wolfgang Radauer
Journal:  N Engl J Med       Date:  2010-05-06       Impact factor: 91.245

2.  Eculizumab for atypical hemolytic-uremic syndrome.

Authors:  Jens Nürnberger; Thomas Philipp; Oliver Witzke; Anabelle Opazo Saez; Udo Vester; Hideo Andreas Baba; Andreas Kribben; Lothar Bernd Zimmerhackl; Andreas R Janecke; Mato Nagel; Michael Kirschfink
Journal:  N Engl J Med       Date:  2009-01-29       Impact factor: 91.245

3.  Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.

Authors:  M Cugno; R Gualtierotti; I Possenti; S Testa; F Tel; S Griffini; E Grovetti; S Tedeschi; S Salardi; D Cresseri; P Messa; G Ardissino
Journal:  J Thromb Haemost       Date:  2014-07-16       Impact factor: 5.824

Review 4.  Atypical hemolytic-uremic syndrome.

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

5.  Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings.

Authors:  Sibylle Tschumi; Mathias Gugger; Barbara S Bucher; Magdalena Riedl; Giacomo D Simonetti
Journal:  Pediatr Nephrol       Date:  2011-08-30       Impact factor: 3.714

6.  Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome.

Authors:  Elena B Volokhina; Nicole C A J van de Kar; Grethe Bergseth; Thea J A M van der Velden; Dineke Westra; Jack F M Wetzels; Lambertus P van den Heuvel; Tom Eirik Mollnes
Journal:  Clin Immunol       Date:  2015-06-23       Impact factor: 3.969

7.  Extracts of wheat gluten activate complement via the alternative pathway.

Authors:  D J Unsworth; R Würzner; D L Brown; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1993-12       Impact factor: 4.330

8.  Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation.

Authors:  Jean-Claude Davin; Valentina Gracchi; Antonia Bouts; Jaap Groothoff; Lisa Strain; Tim Goodship
Journal:  Am J Kidney Dis       Date:  2009-10-25       Impact factor: 8.860

Review 9.  Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches.

Authors:  Magdalena Riedl; Fadi Fakhouri; Moglie Le Quintrec; Damien G Noone; Therese C Jungraithmayr; Veronique Fremeaux-Bacchi; Christoph Licht
Journal:  Semin Thromb Hemost       Date:  2014-06-09       Impact factor: 4.180

Review 10.  Overview of complement activation and regulation.

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  Semin Nephrol       Date:  2013-11       Impact factor: 5.299
View more
  3 in total

1.  Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy.

Authors:  Liang Zheng; Di Zhang; Wenjing Cao; Wen-Chao Song; X Long Zheng
Journal:  Blood       Date:  2019-08-13       Impact factor: 22.113

2.  Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.

Authors:  C Wehling; O Amon; M Bommer; B Hoppe; K Kentouche; G Schalk; R Weimer; M Wiesener; B Hohenstein; B Tönshoff; R Büscher; H Fehrenbach; Ö-N Gök; M Kirschfink
Journal:  Clin Exp Immunol       Date:  2016-11-25       Impact factor: 4.330

3.  A Case Report of Atypical Hemolytic Uremic Syndrome in a Two-Month-Old Infant With a Negative Reported Genetic Profile and Five-Year Follow-Up on Eculizumab.

Authors:  Siddharth Shah; Laith Sweis
Journal:  Cureus       Date:  2020-09-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.